Document is current
Any future updates will be listed below
-
Authors
Lee, Jiyoung
Kawasaki, Tomoyuki
Tabata, Lilika
Chen, Junlong
Uchiyama, Toru
Yamazaki, Satoshi
Umezawa, Akihiro
Akutsu, Hidenori
-
Funding
Funding for this research was provided by:
National Center for Child Health and Development (2024C-26 and 2025C-8)
National Center for Child Health and Development (2022A-2)
The Japan Agency for Medical Research and Development (24be0704001h0005 and 24bm1323001h0302)
- License Information
-
More Information
Article History
Received: 7 January 2026
Accepted: 7 August 2026
First Online: 19 August 2026
Declarations
Ethics approval and consent to participate: All experiments involving human pluripotent stem cells were approved by the Institutional Review Board of the National Center for Child Health and Development. The human induced pluripotent stem cell (iPSC) lines used in this study were previously established from healthy donor cells under the approved project entitled “Establishment and Characterization of Induced Pluripotent Stem Cells Derived from Healthy Donor Cells” (approval number NCCHD-1126; approved on December 24, 2020). The use of human iPSC- and ES cell–based experimental systems for studies of hematopoietic differentiation was additionally approved under the project entitled “Studies on Bone Marrow and Blood Cell Differentiation from Human ES Cells” (approval number NCCHD-ES#61; approved on June 19, 2024). In compliance with the Declaration of Helsinki, informed consent was obtained from all cell donors. Human cells in this study were utilized in full compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Ministry of Health, Labor, and Welfare (MHLW), Japan; Ministry of Education, Culture, Sports, Science and Technology (MEXT, Japan) and performed in full compliance with the Ethical Guidelines for Clinical Studies (Ministry of Health, Labor, and Welfare, Japan). All animal experiments were approved by the Institutional Animal Care and Use Committee of the National Center for Child Health and Development under the approved project entitled “Research on Regenerative Medicine and Cell Therapy Using Mesenchymal Stem Cells, Induced Pluripotent Stem Cells, and Embryonic Stem Cells” (approval number: A2003-002; initially approved on February 28, 2011), and were conducted in accordance with the basic guidelines for the conduct of animal experiments under the jurisdiction of the Ministry of Health, Labour and Welfare (Notification No. 0220–1 of February 20, 2015). The work has been reported in line with the ARRIVE guidelines 2.0.
Consent for publication: Not applicable.
Competing interests: The authors declare no competing interests.
